ElevateBio

• 25/05/2023
• Series D
• $401,000,000

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, ElevateBio BaseCamp is a purpose-built, technology-enabled manufacturing platform offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities for viral vectors, RNA, and cell therapy production. Through BaseCamp, its expanding footprint, and its next-generation enabling technologies, ElevateBio is rapidly growing its collaborations with industry partners while also selectively developing its own portfolio of cellular and genetic medicines.

ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

---

---